In a double-blind, randomised, placebo-controlled study, published in Functional Foods in Health and Disease, Xeya Modern Shatavari showed meaningful improvements across a wide range of menopausal symptoms.
NXT USA’s branded ingredient is based on the Ayurvedic herb shatavari (Asparagus racemosus) and is standardised to a market-high 15% shatavarins.
This high standardisation allows for clinically effective support at low doses of just 50-100mg.
The 120-day study, conducted at Lifeline Hospital & Research Centre in India, included 75 early perimenopausal women aged 40-50 years old with mild-to-moderate symptoms such as hot flushes and night sweats.
Participants in the study who took 100mg of Xeya experienced a significant 77.3% improvement in somatic symptoms, including hot flushes, fatigue and sleep disturbances.
They also had a 74.5% improvement in psychological symptoms, including mood swings, anxiety and brain fog, as measured by the Menopause Rating Scale, a tool widely used in clinical research and practice.
At doses of both 50 and 100mg, Xeya Modern Shatavari significantly decreased the Menopausal Rating Scale by 51.4% and 72.9%, respectively, compared with 22.8% in the placebo group.
The Menstrual Symptoms Questionnaire score significantly improved by 166.7% and 178.8% in the 50mg and 100mg groups, compared with a 35.9% improvement in the placebo group.
The Hot Flash Weekly Weighted Scores significantly dropped by 27.6% and 39.8% in the two treatment groups, compared with a 7.7% increase in the placebo group.
Menstrual symptoms, particularly spasmodic and congestive dysmenorrhoea, also showed marked improvement in the Xeya Modern Shatavari group.
The ovarian follicle count also significantly increased, by 34.4% and 51.9% in the two treatment arms, compared with no change in the placebo group.
Notably, dose-dependent modulation was observed for four separate hormones: follicle-stimulating hormone (FSH), luteinising hormone (LH), anti-Müllerian hormone (AMH) and 17β-oestradiol (E2).
Skin and hair quality also improved.
“These findings extend beyond traditional anecdotal or preclinical evidence, offering robust clinical support for shatavari as a natural, multi-targeted therapeutic option to promote women’s health,” researchers commented.
“These findings align with a growing body of evidence supporting the adaptogenic and hormone-balancing effects of A. racemosus in women’s health,” concluded the research team, “reinforcing the feasibility of integrating [Xeya Modern Shatavari] as a bioactive ingredient in functional foods or dietary supplements designed for perimenopausal and menopausal support.”